JW (Cayman) Therapeutics Co. Ltd

SEHK:2126 Stock Report

Market Cap: HK$836.5m

JW (Cayman) Therapeutics Future Growth

Future criteria checks 2/6

JW (Cayman) Therapeutics is forecast to grow earnings and revenue by 27.7% and 49.9% per annum respectively. EPS is expected to grow by 29.7% per annum. Return on equity is forecast to be -25.6% in 3 years.

Key information

27.7%

Earnings growth rate

29.7%

EPS growth rate

Biotechs earnings growth30.1%
Revenue growth rate49.9%
Future return on equity-25.6%
Analyst coverage

Low

Last updated01 Mar 2024

Recent future growth updates

Recent updates

JW (Cayman) Therapeutics Co. Ltd (HKG:2126): When Will It Breakeven?

Feb 03
JW (Cayman) Therapeutics Co. Ltd (HKG:2126): When Will It Breakeven?

Earnings and Revenue Growth Forecasts

SEHK:2126 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,202-193-184N/A1
12/31/2025575-470-450N/A2
12/31/2024342-550-692N/A2
12/31/2023196-681-621N/A2
6/30/2023167-797-483-404N/A
3/31/2023157-822-560-470N/A
12/31/2022146-846-637-537N/A
9/30/2022121-849-681-594N/A
6/30/202297-851-724-651N/A
3/31/202264-777-711-606N/A
12/31/202131-702-698-561N/A
9/30/202115-998-638-498N/A
6/30/2021-1-1,294-577-435N/A
3/31/20210-1,479-488-348N/A
12/31/2020N/A-1,664-398-261N/A
9/30/20203-1,295-386-227N/A
6/30/20206-925-374-192N/A
3/31/20206-779-338-190N/A
12/31/20195-633-303-189N/A
12/31/20180-273-150-106N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2126 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2126 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2126 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2126's revenue (49.9% per year) is forecast to grow faster than the Hong Kong market (8.1% per year).

High Growth Revenue: 2126's revenue (49.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2126 is forecast to be unprofitable in 3 years.


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.